Targanta Therapeutics Corporation
Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2022
Cumberland Pharmaceuticals sues Melinta and Targanta over alleged contract breach
Lawsuit filed
Cumberland Pharmaceuticals filed a lawsuit against Melinta Therapeutics and Targanta Therapeutics in the Southern District of New York. The complaint alleges breach of a contract concerning the development of a pharmaceutical product. According to the complaint, the defendants failed to pay $1 million in fixed payments. Cumberland seeks damages and other relief. These are allegations contained in the complaint and do not constitute a court determination.
Cumberland Pharmaceuticals filed suit against Melinta Therapeutics and Targanta Therapeutics in the Southern District of New York, alleging breach of a contract concerning development of a pharmaceutical product. The complaint says the defendants failed to pay $1 million in fixed payments; Cumberland seeks damages and other relief. These are allegations in the complaint, not a court determination.
Source excerpt
On Wednesday, Cumberland Pharmaceuticals filed a suit in the Southern District of New York against Melinta Therapeutics, LLC and Targanta Therapeutics Corporation over allegations that the defendants breached a contract they held with the plaintiff regarding the development of a pharmaceutical product.
The complaint concludes that the defendant breached a “valid, enforceable contract” with the plaintiff. Cumberland is seeking $1,000,000 in damages, prejudgment interest, litigation costs, and any other relief deemed proper by the court.